                         SEQUENCE LISTING

<110>  VECT-HORUS
       CNRS
       UNIVERSITE AIX MARSEILLE
 
<120>  COMPOSITIONS AND METHODS FOR DRUG DELIVERY

<130>  B1687PC00

<160>  5     

<170>  PatentIn version 3.3

<210>  1
<211>  8
<212>  PRT
<213>  Artificial

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = (D)-cys

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa = Thz

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa = Pen

<400>  1

Xaa Met Xaa Arg Leu Arg Gly Xaa 
1               5               


<210>  2
<211>  8
<212>  PRT
<213>  Artificial

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = (D)-Cys

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa = Thz

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa = Sar

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa = Pen

<400>  2

Xaa Met Xaa Arg Leu Arg Xaa Xaa 
1               5               


<210>  3
<211>  8
<212>  PRT
<213>  Artificial

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = D-Cys

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa = Pip

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa = Sar

<400>  3

Xaa Met Xaa Arg Leu Arg Xaa Cys 
1               5               


<210>  4
<211>  8
<212>  PRT
<213>  Artificial

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = (D)-cys

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa = Pip

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa = Pen

<400>  4

Xaa Met Xaa Arg Leu Arg Gly Xaa 
1               5               


<210>  5
<211>  8
<212>  PRT
<213>  Artificial

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = (D)-cys

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa = Pip

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa = Sar

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa = Pen

<400>  5

Xaa Met Xaa Arg Leu Arg Xaa Xaa 
1               5               


